from the Scheme of Arrangement booklet put out when Sienna and...

from the Scheme of Arrangement booklet put out when Sienna and BD1 merged a couple of points i found which, along with my previous view confirm that this looks to be a storm in a tea cup.

In terms of the reasonableness test that IFF and Walker are talking about - there were a bunch of BD1 strategic intentions mentioned in the booklet...I have just highlighted the one which mentions Lung....it is only 1 of many balls the BD1 leadership team were juggling....Nowhere does it say we will prioritise lung over everything else...that would be very 'unreasonable' and a dumb decision by the leadership team I would think (thankfully, they are much smarter than that).

6.10 BARD1's intentions if the Scheme is implemented
Key strategic initiatives for the Merged Group to enable sustainable business growth
and achievement of corporate objectives to increase revenue streams, expand the
diagnostics pipeline, secure partners and increase shareholder value include those
set out below.

Accelerate development of the BARD1 autoantibody pipeline towards
commercialisation
As outlined in section 6.3, BARD1 intends to prioritise the development of its
lead BARD1-Ovarian test for early detection of ovarian cancer in high-risk
women with HBOC. Successful commercialisation of the BARD1-Ovarian test
is expected to validate the clinical utility and commercial potential of the
BARD1 autoantibody technology and its further application to breast, lung and
other cancers.

and further on....

6.19 Performance Shares
As at the date of this Scheme Booklet, BARD1 has 217,003,236 Performance Shares on
issue.
Each Performance Share will convert into one BARD1 Share on the announcement by
BARD1 to the ASX of the following prior to the Expiry Date:
• the clinical trial of the blood test developed by BARD1AG S.A. for the detection of lung
cancer (BBLC Test) has been completed;
• the clinical trial involved at least 2,000 participants, and returned a detection rate
greater than 80%, and false positive results of less than 20%; and
• the results of the clinical trial provide statistically significant evidence that the BBLC
Test provides an outcome equal or superior to the current "gold standard" CT Scan,
which has a detection rate of less than 80%, and returns false positive results of more
than 20%. (together, the Milestone)

Performance Shares expire on 9 June 2021 (Expiry Date), being 5 years from the date of
their issue. Performance Shares were released from escrow on 20 June 2018.

Gone from Hold in previous message to 'buy' again. this is just a distraction in my view.